Azzad Asset Management Inc. ADV Trims Position in Hologic, Inc. $HOLX

Azzad Asset Management Inc. ADV lowered its holdings in Hologic, Inc. (NASDAQ:HOLX) by 48.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,978 shares of the medical equipment provider’s stock after selling 14,000 shares during the period. Azzad Asset Management Inc. ADV’s holdings in Hologic were worth $1,011,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in HOLX. Winnow Wealth LLC acquired a new stake in Hologic in the 3rd quarter worth about $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 273 shares during the period. Root Financial Partners LLC acquired a new stake in shares of Hologic in the third quarter worth approximately $27,000. SJS Investment Consulting Inc. boosted its position in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 362 shares during the last quarter. Finally, Loomis Sayles & Co. L P purchased a new stake in Hologic in the second quarter valued at approximately $33,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Mizuho downgraded Hologic from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $70.00 to $78.00 in a research report on Thursday, October 23rd. Raymond James Financial downgraded Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Finally, Leerink Partners boosted their target price on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a report on Tuesday, October 21st. Two investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, Hologic has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $75.02 on Tuesday. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.36. The business has a 50-day moving average of $74.88 and a 200-day moving average of $71.38. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The company has a market capitalization of $16.75 billion, a price-to-earnings ratio of 31.26, a PEG ratio of 2.23 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.87 earnings per share. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.